Regeneron Pharmaceuticals
REGN
$13.92 (2.54%)
1D
1W
3M
1Y
5Y
ALL
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 2 days ago • REGN
Regeneron: Still A Biotech JuggernautBloomberg Markets and Finance • 3 days ago • REGN
Trump Says Pharmaceutical Tariffs Coming in Near FutureReuters • 3 days ago • REGN
Trump says US pharma tariffs coming in not-too-distant futureCNBC • 8 days ago • REGN
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkbackCNBC Television • 8 days ago • REGN
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocksCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.